Results 61 to 70 of about 13,113,839 (405)

FoxO1 signaling in B cell malignancies and its therapeutic targeting

FEBS Letters, EarlyView.
FoxO1 has context‐specific tumor suppressor or oncogenic character in myeloid and B cell malignancies. This includes tumor‐promoting properties such as stemness maintenance and DNA damage tolerance in acute leukemias, or regulation of cell proliferation and survival, or migration in mature B cell malignancies.
Krystof Hlavac, Petra Pavelkova, Laura Ondrisova, Marek Mraz   +3 more
wiley   +1 more source

Artificial Intelligence for In Silico Clinical Trials: A Review [PDF]

arXiv, 2022
A clinical trial is an essential step in drug development, which is often costly and time-consuming. In silico trials are clinical trials conducted digitally through simulation and modeling as an alternative to traditional clinical trials. AI-enabled in silico trials can increase the case group size by creating virtual cohorts as controls. In addition,
arxiv  

Sample size for a non-inferiority clinical trial with time-to-event data in the presence of competing risks [PDF]

Journal of Biopharmaceutical Statistics, 2018, 28:797-807, 2018
The analysis and planning methods for competing risks model have been described in the literatures in recent decades, and non-inferiority clinical trials are helpful in current pharmaceutical practice. Analytical methods for non-inferiority clinical trials in the presence of competing risks were investigated by Parpia et al., who indicated that the ...
arxiv   +1 more source

Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical, and Physician and Patient Barriers to Cancer Clinical Trial Participation

Journal of the National Cancer Institute, 2019
Background Barriers to cancer clinical trial participation have been the subject of frequent study, but the rate of trial participation has not changed substantially over time. Studies often emphasize patient-related barriers, but other types of barriers
J. Unger, R. Vaidya, D. Hershman, L. Minasian, M. Fleury   +4 more
semanticscholar   +1 more source

Insights into PI3K/AKT signaling in B cell development and chronic lymphocytic leukemia

FEBS Letters, EarlyView.
This Review explores how the phosphoinositide 3‐kinase and protein kinase B pathway shapes B cell development and drives chronic lymphocytic leukemia, a common blood cancer. It examines how signaling levels affect disease progression, addresses treatment challenges, and introduces novel experimental strategies to improve therapies and patient outcomes.
Maike Buchner
wiley   +1 more source

The effect of food on the pharmacokinetics of WXFL10203614, a potential selective JAK1 inhibitor, in healthy Chinese subjects

Frontiers in Pharmacology, 2022
Objective: This study was performed to investigate the effect of food on the pharmacokinetics (PK) of WXFL10203614 in healthy Chinese subjects.Methods: This was a randomized, open-label, single-dose, two-treatment (fed vs fasted), two-period, two ...
Kai Huang, Yunfei Shi, Nannan Chu, Linling Que, Ying Ding, Zhenzhong Qian, Wei Qin, Xianghong Gu, Jiakun Wang, Zhiwei Zhang, Jianguo Xu, Qing He   +11 more
doaj   +1 more source

Implementing the EffTox dose-finding design in the Matchpoint trial [PDF]

, 2017
Background: The Matchpoint trial aims to identify the optimal dose of ponatinib to give with conventional chemotherapy consisting of fludarabine, cytarabine and idarubicin to chronic myeloid leukaemia patients in blastic transformation phase.
Billingham, Lucinda, Brock, Kristian, Copland, Mhairi, Siddique, Shamyla, Sirovica, Mirjana, Yap, Christina   +5 more
core   +4 more sources

Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension

Journal of the American Medical Association (JAMA), 2018
Importance Patient-reported outcome (PRO) data from clinical trials can provide valuable evidence to inform shared decision making, labeling claims, clinical guidelines, and health policy; however, the PRO content of clinical trial protocols is often ...
M. Calvert, Derek G Kyte, R. Mercieca-Bebber, A. Slade, A. Chan, M. King, Amanda Hunn, A. Bottomley, A. Regnault, C. Ells, D. O’Connor, D. Revicki, D.walaa badawy, D. Altman, E. Basch, G. Velikova, G. Price, H. Draper, J. Blazeby, Jane A. Scott, J. Coast, J. Norquist, Julia M. Brown, K. Haywood, L. L. Johnson, Lisa Campbell, L. Frank, M. von Hildebrand, M. Brundage, M. Palmer, P. Kluetz, R. Stephens, R. Golub, S. Mitchell, T. Groves   +34 more
semanticscholar   +1 more source

Making tau amyloid models in vitro: a crucial and underestimated challenge

FEBS Letters, EarlyView.
This review highlights the challenges of producing in vitro amyloid assemblies of the tau protein. We review how accurately the existing protocols mimic tau deposits found in the brain of patients affected with tauopathies. We discuss the important properties that should be considered when forming amyloids and the benchmarks that should be used to ...
Julien Broc, Clara Piersson, Yann Fichou
wiley   +1 more source

A Randomized, Double-Blind, Single-Dose Study Comparing the Biosimilarity of HOT-1010 With Bevacizumab (Avastin®) in Chinese Healthy Male Subjects

Frontiers in Pharmacology, 2021
Objective: This study was conducted to compare the pharmacokinetics, safety and immunogenicity of HOT-1010 with bevacizumab (Avastin®) in Chinese healthy male subjects.Methods: A single-center, randomized, double-blind, single-dose, parallel trial was ...
Kai Huang, Linling Que, Ying Ding, Nannan Chu, Zhenzhong Qian, Yunfei Shi, Wei Qin, Zhenni Li, Yuanxin Chen, Xianghong Gu, Jiakun Wang, Lin Zhang, Jisheng Zhang, Xiangyang Zhu, Yongmin Yang, Yuan Tang, Qing He   +16 more
doaj   +1 more source